Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xoma has been designated as a subcontractor to manufacture antibody therapeutics for the US government.
Subscribe to our email newsletter
The subcontract was made under a deal between SRI International in California, and the National Institute of Allergy and Infectious Diseases (NIAID). SRI International was awarded a $56.9 million contract to provide preclinical services to the NIAID project.
Xoma and SRI are negotiating the final terms of the subcontract, which will run for 5 years and is expected to reach as much as $28.1 million. Successful negotiation of the new subcontract would bring the total of Xoma’s governmental contract awards to approximately $60 million since March of 2005.
“We are particularly pleased to play such a central role in the development of products deemed to be important for critical biodefense and infectious disease-related products,” said John Castello, president, and CEO of Xoma.
SRI International is a nonprofit research and development organization. SRI has worked for many years with NIAID’s division of AIDS conducting safety, formulation, and clinical manufacturing projects, as well as with the NIAID biodefense safety, vaccine, and screening programs.